Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
clinical trials
deals
3
×
life sciences
national blog main
national top stories
roche
3
×
boston
fda
investing
san francisco blog main
san francisco top stories
alexion pharmaceuticals
alnylam pharmaceuticals
amgen
avapritinib
blueprint medicines
boehringer ingelheim
cancer
cancer drugs
cobimetinib
cstone pharmaceuticals
dicerna pharamceuticals
eli lilly
european medicines agency
fisogatinib
flatiron health
genentech
hepatitis b
hepatitis b virus
hepatocellular carcinoma
hereditary transthyretin amyloidosis
ipo
jeff albers
medullary thyroid cancer
non-small cell lung cancer
patisiran
pralsetinib
What
drug
medicines
3
×
cancer
research
roche
team
approval
blueprint
candidate
caught
causing
currently
despite
dicerna
disease
eye
family
fda
gene
hardest
hepatitis
hit
hottest
hunters
intended
ipo
marketing
muscle
pact
pay
pharma
pharmaceuticals
producing
protein
proteins
ras
reels
regulatory
ret
review
Language
unset
Current search:
roche
×
deals
×
medicines
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug